BMS/Pfizer gain FDA nod for Eliquis in 2012, after all
This article was originally published in Scrip
With the US FDA's decision on Bristol-Myers Squibb's and Pfizer's anticoagulant Eliquis (apixaban) not expected until 17 March, the companies' notice they would not provide detailed information on the 28 December approval until the following week might be a hint that even they were caught off guard by the early verdict – even though it was the second go-around for the drug's application at the agency.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.